Nonsteroidal Anti-Inflammatory Drugs Impact on the Outcomes of Hospitalized Patients with Clostridium difficile Infection

References

• Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–455. doi:10.1086/65170620307191
   PubMed Web of Science ®Google Scholar
• Marciniak C, Chen D, Stein AC, Semik PE. Prevalence of Clostridium difficile colonization at admission to rehabilitation. Arch Phys Med Rehabil. 2006;87(8):1086–1090. doi:10.1016/j.apmr.2006.03.02016876554
   PubMed Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48.29462280
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14(6):929–931. doi:10.3201/eid1406.07144718507904
   PubMed Web of Science ®Google Scholar
• King A, Mullish BH, Williams HRT, Aylin P. Comparative epidemiology of Clostridium difficile infection: England and the USA. Int J Qual Health Care. 2017;29(6):785–791. doi:10.1093/intqhc/mzx12029025123
   PubMed Web of Science ®Google Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–834. doi:10.1056/NEJMoa140891325714160
   PubMed Web of Science ®Google Scholar
• Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol. 2013;6(1):53–68. doi:10.1177/1756283X12454590
   PubMed Web of Science ®Google Scholar
• Peniche AG, Savidge TC, Dann SM. Recent insights into Clostridium difficile pathogenesis. Curr Opin Infect Dis. 2013;26(5):447–453. doi:10.1097/01.qco.0000433318.82618.c623982235
   PubMed Web of Science ®Google Scholar
• Eze P, Balsells E, Kyaw MH, Nair H. Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis. J Glob Health. 2017;7(1):010417. doi:10.7189/jogh.07.01041728607673
   PubMed Web of Science ®Google Scholar
• Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid–suppressive agents and the risk of community-acquired Clostridium difficile–associated disease. JAMA. 2005;294(23):2989–2995. doi:10.1001/jama.294.23.298916414946
   PubMed Web of Science ®Google Scholar
• Suissa D, Delaney JA, Dial S, Brassard P. Non-steroidal anti-inflammatory drugs and the risk of Clostridium difficile-associated disease. Br J Clin Pharmacol. 2012;74(2):370–375. doi:10.1111/j.1365-2125.2012.04191.x22283873
   PubMed Web of Science ®Google Scholar
• Permpalung N, Upala S, Sanguankeo A, Sornprom S. Association between NSAIDs and Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Canadian J Gastroenterol Hepatol. 2016;2016:7431838. doi:10.1155/2016/7431838
   Web of Science ®Google Scholar
• Davis JS, Lee HY, Kim J, et al. Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic. Open Heart. 2017;4(1):e000550. doi:10.1136/openhrt-2016-00055028674622
   PubMed Web of Science ®Google Scholar
• Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general US population. Pharmacoepidemiol Drug Saf. 2014;23(1):43–50. doi:10.1002/pds.v23.123723142
   PubMed Web of Science ®Google Scholar
• Rogers MAM, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect. 2016;22(2):178.e171–178.e179. doi:10.1016/j.cmi.2015.10.003
   PubMed Web of Science ®Google Scholar
• Maseda D, Zackular JP, Trindade B, et al. Nonsteroidal anti-inflammatory drugs alter the microbiota and exacerbate Clostridium difficile colitis while dysregulating the inflammatory response. MBio. 2019;10(1):e02282–02218. doi:10.1128/mBio.02282-1830622186
   PubMed Web of Science ®Google Scholar
• Muñoz-Miralles J, Trindade BC, Castro-Córdova P, et al. Indomethacin increases severity of Clostridium difficile infection in mouse model. Future Microbiol. 2018;13(11):1271–1281. doi:10.2217/fmb-2017-031130238771
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–498. doi:10.1038/ajg.2013.423439232
   PubMed Web of Science ®Google Scholar
• Mora AL, Salazar M, Pablo-Caeiro J, et al. Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci. 2012;343(4):277–280. doi:10.1097/MAJ.0b013e31822f42eb21934595
   PubMed Web of Science ®Google Scholar
• Chowdhry M, Bhaty M, Huggett A, et al. Sa1843 - opioid use in Clostridium Difficile infection is associated with severe disease and prolonged hospitalization. Gastroenterology. 2018;154(6):S–416. doi:10.1016/S0016-5085(18)31666-4
   Web of Science ®Google Scholar
• Kitchen J, Kane D. Non-steroidal anti-inflammatory drug prescriptions in hospital inpatients: are we assessing the risks? Ir J Med Sci. 2010;179(3):357–360. doi:10.1007/s11845-010-0496-020512664
   PubMed Web of Science ®Google Scholar
• Alvarez PA, Nguyen DT, Schutt R, et al. In-hospital use of non-steroidal anti-inflammatory drugs in patients with heart failure in academic centers in the United States. Int J Risk Saf Med. 2016;28(4):181–188. doi:10.3233/JRS-17073628582878
   PubMedGoogle Scholar
• Giardina C, Cutroneo PM, Mocciaro E, et al. Adverse drug reactions in hospitalized patients: results of the FORWARD (Facilitation of Reporting in Hospital Ward) study. Front Pharmacol. 2018;9:350. doi:10.3389/fphar.2018.0035029695966
   PubMed Web of Science ®Google Scholar
• Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis. 2009;15(3):415–422. doi:10.3201/eid1503.08031219239754
   PubMed Web of Science ®Google Scholar
• Pepin J, Vo TT, Boutros M, et al. Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. Dis Colon Rectum. 2009;52(3):400–405. doi:10.1007/DCR.0b013e31819a69aa19333038
   PubMed Web of Science ®Google Scholar
• Fujitani S, George WL, Murthy AR. Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol. 2011;32(3):220–228. doi:10.1086/65833621460506
   PubMed Web of Science ®Google Scholar
• Stevens DL. Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis. 1995;21(4):977–980. doi:10.1093/clinids/21.4.9778645850
   PubMed Web of Science ®Google Scholar
• Basille D. Non-steroidal anti-inflammatory drugs may worsen the course of community-acquired pneumonia: a cohort study. Lung. 2017;195(2):201–208. doi:10.1007/s00408-016-9973-1.28005149
   PubMed Web of Science ®Google Scholar
• Lepelletier D, Pinaud V, Le Conte P, et al. Is there an association between prior anti-inflammatory drug exposure and occurrence of peritonsillar abscess (PTA)? A national multicenter prospective observational case-control study. Eur J Clin Microbiol Infect Dis. 2017;36(1):57–63. doi:10.1007/s10096-016-2770-127604832
   PubMed Web of Science ®Google Scholar
• Le Turnier P, Boutoille D, Joyau C, Veyrac G, Asseray N. Bacterial infections and NSAIDs exposure? Seek septic complications. Eur J Intern Med. 2017;41:e33–e34. doi:10.1016/j.ejim.2017.03.00428302389
   PubMed Web of Science ®Google Scholar
• Eisen DP. Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-inflammatory drugs on sepsis. Intensive Care Med. 2012;38(8):1249–1257. doi:10.1007/s00134-012-2570-822531881
   PubMed Web of Science ®Google Scholar
• Yin Z, Wang Y, Whittell Louise R, et al. DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chem Biol. 2014;21(4):481–487. doi:10.1016/j.chembiol.2014.02.00924631121
   PubMedGoogle Scholar
• Chan EWL, Yee ZY, Raja I, Yap JKY. Synergistic effect of non-steroidal anti-inflammatory drugs (NSAIDs) on antibacterial activity of cefuroxime and chloramphenicol against methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist. 2017;10:70–74. doi:10.1016/j.jgar.2017.03.01228673701
   PubMed Web of Science ®Google Scholar
• Gágyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ. 2015;351:h6544. doi:10.1136/bmj.h654426698878
   PubMed Web of Science ®Google Scholar
• Garellek J, Tin K, Srikanthan R, et al. Aspirin, statins and stool PH levels in preventing clostridium difficile infection. Gastroenterology. 2017;152(5):S950. doi:10.1016/S0016-5085(17)33232-8
   Web of Science ®Google Scholar
• Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis. 2008;46(Supplement_1):S43–S49. doi:10.1086/52186118177221
   PubMed Web of Science ®Google Scholar
• Zahar JR, Schwebel C, Adrie C, et al. Outcome of ICU patients with Clostridium difficile infection. Crit Care. 2012;16(6):R215. doi:10.1186/cc1185223127327
   PubMed Web of Science ®Google Scholar
• Chen X, Katchar K, Goldsmith JD, et al. A mouse model of Clostridium difficile-associated disease. Gastroenterology. 2008;135(6):1984–1992. doi:10.1053/j.gastro.2008.09.00218848941
   PubMed Web of Science ®Google Scholar